Assessing Veracyte (VCYT) Valuation After Recent Share Price Volatility

Simply Wall St

Tue, February 17, 2026 at 2:06 PM GMT+9 3 min read

In this article:

VCYT

+1.76%

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

What Veracyte’s Recent Numbers Tell You

Veracyte (VCYT) has drawn investor attention after recent share price swings, with the stock showing a 1.8% gain over the past day but weaker performance over the past month and past 3 months.

At a last close of US$35.77, Veracyte’s diagnostics-focused business generates US$495.141m in revenue and US$30.317m in net income. Its value score of 3 suggests some investors may see room for further fundamental assessment.

See our latest analysis for Veracyte.

While the share price has edged up over the past day, Veracyte’s 30-day share price return of a 13.95% decline and year to date share price return of a 15.62% decline contrast with its 3-year total shareholder return of 40.49%. This points to fading short term momentum against a stronger multi year record.

If Veracyte’s recent moves have you reassessing your watchlist, this could be a good moment to broaden your search. You may wish to use our screener of 25 healthcare AI stocks as a starting point for other ideas in the space.

So with Veracyte trading at US$35.77, showing an intrinsic discount of 37.50% and a 33.26% discount to analyst targets, is the market overlooking value here, or already baking in all the future growth potential?

Most Popular Narrative: 24.7% Undervalued

With Veracyte last traded at $35.77 against a narrative fair value of about $47.50, the valuation story hinges on how its cancer testing portfolio scales from here.

Increasing clinical evidence, integration of AI/digital pathology, partnerships (Helix, biopharma), and a growing GRID/data platform are enhancing Veracyte’s technology differentiation and providing leverage to value-based healthcare models; this strengthens the reimbursement outlook and competitive edge, supporting higher sustainable margins and earnings growth as volumes scale.

Read the complete narrative.

Want to see what is baked into that higher fair value? The narrative leans on rising earnings, wider margins, and a richer future earnings multiple. The exact assumptions may surprise you.

Result: Fair Value of $47.50 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still real pressure points here, including heavy dependence on Decipher and Afirma, as well as ongoing reimbursement and pricing questions that could cap the upside to this story.

Find out about the key risks to this Veracyte narrative.

Another Angle On Valuation

The earlier fair value story leans on future cash flows and growth, but the current P/E of 93.3x tells a different tale. That is far above the US Biotechs average of 22.2x, the peer average of 47.8x, and our fair ratio of 22.3x. This suggests a lot is already priced in, which raises the question: is this a margin of safety or a margin of error?

Story Continues  

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:VCYT P/E Ratio as at Feb 2026

Next Steps

With mixed signals across valuation, growth expectations, and pricing pressure, the real question is what you think happens next. Take a close look at the full picture, weigh both the concerns and the potential, and use our breakdown of 4 key rewards and 1 important warning sign to shape your own view while the market is still debating it.

Looking For More Investment Ideas?

If Veracyte has your attention, do not stop here. The real edge comes from comparing it with other ideas that match your goals and risk comfort.

Target steadier compounding potential by reviewing companies priced below their estimated worth through our list of 54 high quality undervalued stocks before the crowd catches on.

Strengthen your income stream by checking out businesses with resilient payouts in our collection of 13 dividend fortresses that could complement a growth focused portfolio.

Protect your downside by scanning companies that score well on financial resilience using the 83 resilient stocks with low risk scores so you are not caught off guard by hidden weaknesses.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include VCYT.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info